Tag: oncology
Incyte Stock Analysis (INCY): JAKAFI Cliff Looms
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.